| Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia HLM Koskela, S Eldfors, P Ellonen, AJ van Adrichem, H Kuusanmäki, ... New England journal of medicine 366 (20), 1905-1913, 2012 | 870 | 2012 |
| Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ... Cancer discovery 3 (12), 1416-1429, 2013 | 450* | 2013 |
| Functional interaction of VEGF‐C and VEGF‐D with neuropilin receptors T Karpanen, CA Heckman, S Keskitalo, M Jeltsch, H Ollila, G Neufeld, ... The FASEB Journal 20 (9), 1462-1472, 2006 | 389 | 2006 |
| Comparison of solution-based exome capture methods for next generation sequencing AM Sulonen, P Ellonen, H Almusa, M Lepistö, S Eldfors, S Hannula, ... Genome biology 12, 1-18, 2011 | 334 | 2011 |
| Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia HLM Rajala, S Eldfors, H Kuusanmäki, AJ Van Adrichem, T Olson, ... Blood, The Journal of the American Society of Hematology 121 (22), 4541-4550, 2013 | 333 | 2013 |
| Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ... Scientific reports 4 (1), 1-10, 2014 | 326 | 2014 |
| Histone Deacetylase Inhibitors Down-Regulate bcl-2 Expression and Induce Apoptosis in t(14;18) Lymphomas H Duan, CA Heckman, LM Boxer Molecular and cellular biology 25 (5), 1608-1619, 2005 | 322 | 2005 |
| Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors DJ McBride, AK Orpana, C Sotiriou, H Joensuu, PJ Stephens, LJ Mudie, ... Genes, Chromosomes and Cancer 49 (11), 1062-1069, 2010 | 300 | 2010 |
| Negative regulation of bcl-2 expression by p53 in hematopoietic cells Y Wu, JW Mehew, CA Heckman, M Arcinas, LM Boxer Oncogene 20 (2), 240-251, 2001 | 290 | 2001 |
| NF-κB activates Bcl-2 expression in t (14; 18) lymphoma cells CA Heckman, JW Mehew, LM Boxer Oncogene 21 (24), 3898-3908, 2002 | 262 | 2002 |
| Immunogenomic landscape of hematological malignancies O Dufva, P Pölönen, O Brück, MAI Keränen, J Klievink, J Mehtonen, ... Cancer Cell 38 (3), 380-399. e13, 2020 | 154 | 2020 |
| Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer A Malyutina, MM Majumder, W Wang, A Pessia, CA Heckman, J Tang PLoS computational biology 15 (5), e1006752, 2019 | 138 | 2019 |
| Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ... Haematologica 105 (3), 708, 2020 | 137 | 2020 |
| Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia M Kontro, H Kuusanmäki, S Eldfors, T Burmeister, EI Andersson, ... Leukemia 28 (8), 1738-1742, 2014 | 129 | 2014 |
| MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents A Bolomsky, M Vogler, MC Köse, CA Heckman, G Ehx, H Ludwig, J Caers Journal of hematology & oncology 13, 1-19, 2020 | 126 | 2020 |
| JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML R Karjalainen, T Pemovska, M Popa, M Liu, KK Javarappa, MM Majumder, ... Blood, The Journal of the American Society of Hematology 130 (6), 789-802, 2017 | 124 | 2017 |
| The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis CA Heckman, T Holopainen, M Wirzenius, S Keskitalo, M Jeltsch, ... Cancer Research 68 (12), 4754-4762, 2008 | 121 | 2008 |
| The WT1 Protein Is a Negative Regulator of the Normalbcl-2 Allele in t (14; 18) Lymphomas C Heckman, E Mochon, M Arcinas, LM Boxer Journal of Biological Chemistry 272 (31), 19609-19614, 1997 | 112 | 1997 |
| Implementing a functional precision medicine tumor board for acute myeloid leukemia D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... Cancer discovery 12 (2), 388-401, 2022 | 98 | 2022 |
| Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer K Saeed, V Rahkama, S Eldfors, D Bychkov, JP Mpindi, B Yadav, ... European urology 71 (3), 319-327, 2017 | 97 | 2017 |
